<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5835">
  <stage>Registered</stage>
  <submitdate>23/02/2016</submitdate>
  <approvaldate>23/02/2016</approvaldate>
  <nctid>NCT02692703</nctid>
  <trial_identification>
    <studytitle>A Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients With Chronic Hepatitis C Virus (MAGELLAN-2)</studytitle>
    <scientifictitle>A Single-Arm, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 - 6 Infection (MAGELLAN-2)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2015-005616-14</secondaryid>
    <secondaryid>M13-596</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Chronic Hepatitis C</healthcondition>
    <healthcondition>HCV</healthcondition>
    <healthcondition>Hepatitis C Virus</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - ABT-493/ABT-530

Experimental: ABT-493/ABT-530 - ABT-493/ABT-530 for 12 weeks


Treatment: drugs: ABT-493/ABT-530
Tablet

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Percentage of Participants with Sustained Virologic Response 12 weeks After Treatment compared to the historical Sustained Virologic Response 12 weeks. - Hepatitis C virus ribonucleic acid less than the lower limit of quantification 12 weeks after the last dose of study drug.</outcome>
      <timepoint>12 weeks after the last dose of study drug</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>The percentage of participants with on-treatment virologic failure - The percentage of participants with confirmed increase of &gt; 1 log10 IU/mL in HCV RNA above nadir during treatment, confirmed HCV RNA = 100 IU/mL after HCV RNA &lt; LLOQ during treatment, or HCV RNA = LLOQ at the end of treatment with at least 6 weeks of treatment)</outcome>
      <timepoint>Up to Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The percentage of participants with post-treatment relapse - Percentage of participants with confirmed quantifiable HCV RNA between end of treatment and 12 weeks after the last dose of study drug among participants who completed treatment with unquantifiable HCV RNA at the end of treatment.</outcome>
      <timepoint>Up to 12 weeks after the last dose of study drug</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Male or female, at least 18 years of age at time of screening.

          -  Screening laboratory result indicating HCV GT1 - 6 infection.

          -  Subject is a recipient of a cadaveric or living donor liver transplant which was a
             consequence of HCV infection at least 3 months prior to screening Or Subject received
             a cadaveric or living donor kidney at least 3 months before screening.

          -  Subjects must be documented as non-cirrhotic.

          -  Subject is currently taking a stable immunosuppression regimen based on tacrolimus,
             sirolimus, everolimus, mycophenolate mofetil (MMF), mycophenolic acid, azathioprine,
             and/or cyclosporine.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>99</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Female subject who is pregnant, breastfeeding or is considering becoming pregnant
             during the study or for approximately 30 days after the last dose of study drug.

          -  Clinical history of fibrosing cholestatic hepatitis post-transplant.

          -  Re-transplantation of the liver or kidney.

          -  Steroid resistant rejection of the transplanted liver or kidney, or a history of
             rejection treated with high dose steroid within 3 months of screening.

          -  History of post-transplant complications related to hepatic or renal vasculature.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>22/04/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>100</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>29/06/2017</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Royal Prince Alfred Hospital /ID# 149172 - Camperdown</hospital>
    <hospital>Austin Hospital /ID# 149171 - Heidelberg</hospital>
    <postcode>2050 - Camperdown</postcode>
    <postcode>3084 - Heidelberg</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Edmonton</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Toronto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Bergamo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Puerto Rico</country>
      <state>Ponce</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Puerto Rico</country>
      <state>Ssn Juan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Cordoba-(Espana)</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Valencia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Edgbaston, Birmingham</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Leeds</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>AbbVie</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to assess the safety and efficacy of 12 weeks of treatment of
      ABT-493/ABT-530 in adults who are post primary orthotopic liver or renal transplant with
      chronic Hepatitis C Virus infection.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02692703</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Susan Rhee, MD</name>
      <address>AbbVie</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>